Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2024, Номер unknown, С. 189250 - 189250
Опубликована: Дек. 1, 2024
Язык: Английский
World Journal of Clinical Cases, Год журнала: 2025, Номер 13(15)
Опубликована: Янв. 21, 2025
The integration of artificial intelligence (AI) and multiomics has transformed clinical life sciences, enabling precision medicine redefining disease understanding. Scientific publications grew significantly from 2.1 million in 2012 to 3.3 2022, with AI research tripling during this period. Multiomics fields, including genomics proteomics, also advanced, exemplified by the Human Proteome Project achieving a 90% complete blueprint 2021. This growth highlights opportunities challenges integrating into reporting. A review studies case reports was conducted evaluate integration. Key areas analyzed included diagnostic accuracy, predictive modeling, personalized treatment approaches driven tools. Case examples were studied assess impacts on decision-making. enhanced data integration, insights, personalization. Fields like radiomics, genomics, proteomics improved diagnostics guided therapy. For instance, “AI oncopathomics, surgomics project” combined radiomics for surgical decision-making, preoperative, intraoperative, postoperative interventions. applications predicted conditions delirium monitored cancer progression using genomic imaging data. enable standardized analysis, dynamic updates, modeling reports. Traditional often lack objectivity, but enhances reproducibility decision-making processing large datasets. Challenges include standardization, biases, ethical concerns. Overcoming these barriers is vital optimizing advancing medicine. revolutionizing practice. Standardizing reporting addressing ethics quality will unlock their full potential. Emphasizing collaboration transparency essential leveraging tools improve patient care scientific communication.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(7), С. 1132 - 1132
Опубликована: Март 28, 2025
Artificial Intelligence (AI) is transforming pancreaticobiliary endoscopy by enhancing diagnostic accuracy, procedural efficiency, and clinical outcomes. This narrative review explores AI's applications in endoscopic ultrasound (EUS) retrograde cholangiopancreatography (ERCP), emphasizing its potential to address therapeutic challenges diseases. In EUS, AI improves pancreatic mass differentiation, malignancy prediction, landmark recognition, demonstrating high accuracy outperforming traditional guidelines. ERCP, facilitates precise biliary stricture identification, optimizes techniques, supports decision-making through real-time data integration, improving ampulla recognition predicting cannulation difficulty. Additionally, predictive analytics help mitigate complications like post-ERCP pancreatitis. The future of lies multimodal fusion, integrating imaging, genomic, molecular enable personalized medicine. However, such as quality, external validation, clinician training, ethical concerns-like privacy algorithmic bias-must be addressed ensure safe implementation. By overcoming these challenges, has the redefine healthcare, outcomes, care.
Язык: Английский
Процитировано
0
World Journal of Gastrointestinal Surgery, Год журнала: 2025, Номер 17(4)
Опубликована: Март 29, 2025
Despite advances in surgery, chemotherapy, and radiotherapy, the treatment of colorectal cancer (CRC) requires more personalized approaches based on tumor biology molecular profiling. While some relevant mutations have been associated with differential response to immunotherapy, such as RAS BRAF limiting anti-epithelial growth factor receptor drugs or microsatellite instability predisposing susceptibility immune checkpoint inhibitors, role inflammation dictating progression is still under investigation. Several inflammatory biomarkers identified guide patient prognosis. These include neutrophil-lymphocyte ratio, Glasgow prognostic score (GPS) its modified version, lymphocyte-C-reactive protein platelet-lymphocyte ratio. However, these markers are not yet included standard clinical management patients CRC, further research needed evaluate their efficacy different populations. A recent study by Wang et al , published World Journal Gastroenterology sheds light significance pan-immune-inflammation value (PIV) particularly concerning primary location. Specifically, authors found that a high PIV was strongly correlated worse disease-free survival left-sided colon cancer, whereas no association observed right-sided cancer. Integrating location into assessment CRC may improve our ability accurately identify high-risk develop plans likely outcomes.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2024, Номер 16(18), С. 3203 - 3203
Опубликована: Сен. 20, 2024
The primary treatment for operable pancreatic cancer (PC) involves surgery followed by adjuvant therapy. Nevertheless, perioperative or neoadjuvant chemotherapy (CT) may be used to mitigate the likelihood of recurrence and mortality. This network meta-analysis (NMA) assesses comparative efficacy various approaches resectable PC. A thorough search was carried out on January 31, 2023, encompassing PubMed/MEDLINE, Cochrane Library, Embase databases. We incorporated randomized clinical trials (RCTs) that compared surgical interventions with without (neo)adjuvant therapies conducted a fixed-effects Bayesian NMA. presented effect sizes in terms hazard ratios (HRs) overall survival (OS) along 95% credible intervals (95% CrIs). deemed statistically superior when interval (CrI) did not encompass null value (hazard ratio < 1). Treatment rankings were established based surface under cumulative ranking curve (SUCRA). total 24 studies incorporated, comparing 21 treatments isolation. Eleven showed alone, HRs ranging from 0.38 0.73 5-fluorouracil. After exclusion Asia, it found regimen gemcitabine combined nab-paclitaxel most effective (SUCRA, p = 0.99). findings endorse utilization CT, especially multi-agent as favored intervention PC Western nations.
Язык: Английский
Процитировано
0
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2024, Номер unknown, С. 189250 - 189250
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0